NCT02936102: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. |
|
|
| Active, not recruiting | 1 | 154 | Europe, Canada, Japan, US, RoW | FAZ053, PDR001 | Novartis Pharmaceuticals | Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma | 11/24 | 11/24 | | |
